Tenderwize
Retour à la recherche

Open House Biologics Discount Agreement for Epoetin Alfa and Epoetin Zeta

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 30, 2028 · 674 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 12 Epoetin alfa und Epoetin zeta

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

The notice says offers/contracts cannot be submitted via the procurement portal; they must be sent by email with qualif...

Only pharmaceutical companies meeting the AMG and market authorisation requirements for the specific medicines appear e...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Open House conclusion of pharmaceutical discount agreements under Section 130a(8) SGB V for Epoetin alfa and Epoetin zeta.
  • Nationwide supply/performance in Germany.
Afficher le résumé complet

Open House procedure by Techniker Krankenkasse for non-exclusive discount agreements on pharmaceutical products for Epoetin alfa and Epoetin zeta (CPV 33600000). The notice states that all suitable pharmaceutical companies may join during the contract period, with uniform conditions and no individual negotiation. The contract term is up to 24 months from 01/07/2026 to 30/06/2028. No contract value is stated in the provided data. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the procedure communication is via the TK portal communication area/email. Procurement documents are available online, but only the notice text was provided for analysis.

Risques

The notice says offers/contracts cannot be submitted via the procurement portal; they must be sent by email with qualif...

Only pharmaceutical companies meeting the AMG and market authorisation requirements for the specific medicines appear e...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of Section 4(18) AMG for the relevant medicines.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the medicines and/or otherwise be entitled to place them on the market in its own name.

Critères d'attribution

Lot 1

Open House notice field only; award criteria not materially applicable.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Biologics Discount Agreement for Epoetin Alfa and Epoetin Zeta

Lot 1 concerns an Open House discount agreement for the medicinal products Epoetin alfa and Epoetin zeta. Scope is nationwide in Germany. The notice indicates open accession for all eligible pharmaceutical companies, no exclusivity, and no individual negotiation. The lot details come from structured data and notice text.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jun 2026 - Jun 2028

Catégorie

Pharmaceutical products

Critères d'attribution

Open House notice field only; award criteria not materially applicable.

Date limite

Deadline Jun 30, 2028

Détails de la procédure

Date de publication
07 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
317941-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3